Company intelligence / Profile preview

IGUT

Ownership: Private
Development stage: Other

Overview

IGY Life Sciences develops novel IgY antibody-based solutions using a proprietary extraction platform. Their pipeline spans human therapeutics, nutraceuticals for immune/gut health, and animal disease prevention. Some products are already commercialized in the supplement market; others remain under development. No clinical trial results were found.

Therapeutic areas: ImmunologyInfectious Diseases
Modalities: Antibody (specifically IgY antibody)Protein
Industry: Non-Drug Biotech

Partnerships

Not specifically listed; company states openness to partnerships with investors and industry partners.

Beyond the preview

Go deeper on IGUT.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IGUT.

Explore the full profile